OBJECTIVES: Impregnation of antimicrobial agents within biodegradable carriers with osteoconductive properties could provide the means for one-stage surgical treatment of osteomyelitis. In this study, the in vitro and in vivo antibiotic release from this type of bone defect filler was characterized. METHODS: Cylindrical pellets (2.5 x 1.5 mm) were manufactured from bioabsorbable poly(L-lactide-co-glycolide) (PLGA) matrix, ciprofloxacin [8.3 +/- 0.1% (w/w)] and osteoconductive bioactive glass microspheres (90-125 microm) [27 +/- 2% (w/w)]. In vitro studies were carried out to delineate the release profile of the antibiotic. The antimicrobial activity of the release antibiotic was verified with MIC testing. In a time-sequence study in the rabbit, pellets were surgically implanted in the proximal tibia and the antibiotic concentrations achieved in bone were measured at 1, 2, 3, 4, 5 and 6 months. RESULTS: In vitro elution studies showed sustained release of ciprofloxacin at a therapeutic level (>2 microg/mL) over a time period of 4 months. The released ciprofloxacin had maintained its antimicrobial capacity against five standard ATCC strains. In vivo, the delivery system produced high local bone concentrations (247.9 +/- 91.0 mug/g of bone) for a time period of 3 months with no significant systemic exposure. Histomorphometry and micro-CT imaging confirmed new bone formation around the pellets within 3 months as a sign of an independent osteoconductive property of the composite. CONCLUSIONS: The tested composite seems to be a promising option for local therapy of surgically treated bone infections. The main advantages are the antibiotic release for a definite time period with therapeutic concentrations, which may minimize slow residual release at suboptimal concentrations.
OBJECTIVES: Impregnation of antimicrobial agents within biodegradable carriers with osteoconductive properties could provide the means for one-stage surgical treatment of osteomyelitis. In this study, the in vitro and in vivo antibiotic release from this type of bone defect filler was characterized. METHODS: Cylindrical pellets (2.5 x 1.5 mm) were manufactured from bioabsorbable poly(L-lactide-co-glycolide) (PLGA) matrix, ciprofloxacin [8.3 +/- 0.1% (w/w)] and osteoconductive bioactive glass microspheres (90-125 microm) [27 +/- 2% (w/w)]. In vitro studies were carried out to delineate the release profile of the antibiotic. The antimicrobial activity of the release antibiotic was verified with MIC testing. In a time-sequence study in the rabbit, pellets were surgically implanted in the proximal tibia and the antibiotic concentrations achieved in bone were measured at 1, 2, 3, 4, 5 and 6 months. RESULTS: In vitro elution studies showed sustained release of ciprofloxacin at a therapeutic level (>2 microg/mL) over a time period of 4 months. The released ciprofloxacin had maintained its antimicrobial capacity against five standard ATCC strains. In vivo, the delivery system produced high local bone concentrations (247.9 +/- 91.0 mug/g of bone) for a time period of 3 months with no significant systemic exposure. Histomorphometry and micro-CT imaging confirmed new bone formation around the pellets within 3 months as a sign of an independent osteoconductive property of the composite. CONCLUSIONS: The tested composite seems to be a promising option for local therapy of surgically treated bone infections. The main advantages are the antibiotic release for a definite time period with therapeutic concentrations, which may minimize slow residual release at suboptimal concentrations.
Authors: Dario Puppi; Anna Maria Piras; Alessandro Pirosa; Stefania Sandreschi; Federica Chiellini Journal: J Mater Sci Mater Med Date: 2016-01-12 Impact factor: 3.896
Authors: Esther J Lee; Beom Kang Huh; Se Na Kim; Jae Yeon Lee; Chun Gwon Park; Antonios G Mikos; Young Bin Choy Journal: Prog Mater Sci Date: 2017-06-13
Authors: Rosa P Félix Lanao; Anika M Jonker; Joop G C Wolke; John A Jansen; Jan C M van Hest; Sander C G Leeuwenburgh Journal: Tissue Eng Part B Rev Date: 2013-03-01 Impact factor: 6.389
Authors: C Pigrau; B Almirante; D Rodriguez; N Larrosa; S Bescos; G Raspall; A Pahissa Journal: Eur J Clin Microbiol Infect Dis Date: 2008-09-17 Impact factor: 3.267
Authors: Niina Ahola; Minna Veiranto; Noora Männistö; Matti Karp; Jaana Rich; Alexander Efimov; Jukka Seppälä; Minna Kellomäki Journal: Biomatter Date: 2012 Oct-Dec
Authors: Niina Ahola; Noora Männistö; Minna Veiranto; Matti Karp; Jaana Rich; Alexander Efimov; Jukka Seppälä; Minna Kellomäki Journal: Biomatter Date: 2013-01-01